NCT04512287 - PRP for Treatment of Peyronie's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

August 11, 2025

Study Completion Date

August 11, 2025

Conditions

Peyronie DiseaseSexual Dysfunction, PhysiologicalSexual Dysfunction MaleGenital Diseases, Male

Interventions

DRUG

Autologous Platelet Rich Plasma

2 sessions of Autologous PRP will be administered 15 days apart. Each injection will be 0.5 mL of PRP injected into the Peyronie's disease penile plaque.

OTHER

Saline Solution

2 sessions of saline injection will be administered 15 days apart. Each injection will be 0.5 mL of normal saline injected into the Peyronie's disease penile plaque.

Trial Locations (1)

33136

University of Miami, Miami

All Listed Sponsors

lead

University of Miami

OTHER